Christopher W. Cain - Apr 29, 2025 Form 4 Insider Report for Jade Biosciences, Inc. (JBIO)

Role: Director
Signature: /s/ Elizabeth Balta, as attorney-in-fact for Christopher W. Cain
Stock symbol: JBIO
Transactions as of: Apr 29, 2025
Transactions value $: $0
Form type: 4
Date filed: 5/1/2025, 06:07 PM
Previous filing: May 1, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JBIO	Stock Option (Right to Buy)	Award	$0	+23K		$0.00	23K	Apr 29, 2025	Common Stock	23K	$10.14	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase 23,017 shares of the Issuer's common stock, which vests in full on the earlier of (i) April 29, 2026 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer.
F2	Under the Reporting Person's arrangement with Fairmount Funds Management LLC ("Fairmount"), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Content

This option represents a right to purchase 23,017 shares of the Issuer's common stock, which vests in full on the earlier of (i) April 29, 2026 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer.

Under the Reporting Person's arrangement with Fairmount Funds Management LLC ("Fairmount"), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.